Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry

Annals of the New York Academy of Sciences

Volumn 1144, Issue , 2008, Pages 61-73

  Ebner, Karl ^a,b   Muigg, Patrik ^a   Singewald, Georg ^a   Singewald, Nicolas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antidepressant; Anxiety; Anxiolytic; Depression; Emotional behavior; HPA axis; In vivo release; Microdialysis; Neurokinin; NK 1 receptor; NK 1 receptor antagonist; Stress; Stress related disorders; Substance P; Tachykinin

Indexed keywords

DRUG VEHICLE; L 822429; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEIN C FOS; SUBSTANCE P; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; CONFERENCE PAPER; EMOTIONAL STRESS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; LATERAL BRAIN VENTRICLE; LOCUS CERULEUS; MALE; MAZE TEST; NEUROENDOCRINOLOGY; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN INDUCTION; RAT; STRESS; STRIA TERMINALIS; TRANQUILIZING ACTIVITY;

MUS;

EID: 56649105314     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1418.018     Document Type: Conference Paper

References (76)

1. Krase, W., M. Koch & H.U. Schnitzler. 1994. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav. Brain Res. 63 : 81 88.
2. Severini, C., G. Improta, G. Falconieri-erspamer, et al. 2002. The tachykinin peptide family. Pharmacol. Rev. 54 : 285 322.
3. Nawa, H., T. Hirose, H. Takashima, et al. 1983. Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 306 : 32 36.
4. Otsuka, M. & K. Yoshioka. 1993. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73 : 229 308.
5. Regoli, D., A. Boudon & J.L. Fauchere. 1994. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46 : 551 599.
6. Maggi, C.A. 1995. The mammalian tachykinin receptors. Gen. Pharmacol. 26 : 911 944.
7. Ribeiro-da-Silva, A. & T. Hökfelt. 2000. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 34 : 256 271.
8. Hökfelt, T., E. Kuteeva, D. Stanic & A. Ljungdahl. 2004. The histochemistry of tachykinin systems in the brain. In Tachykinins. P. Holzer, Ed. : 63 120. Springer. Heidelberg, Germany.
9. Hökfelt, T., D. Millhorn, K. Seroogy, et al. 1987. Coexistence of peptides with classical neurotransmitters. Experientia 43 : 768 780.
10. Merighi, A. 2002. Costorage and coexistence of neuropeptides in the mammalian CNS. Prog. Neurobiol. 66 : 161 190.
11. Unger, T., S. Carolus, G. Demmert, D. Ganten, et al. 1988. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ. Res. 63 : 812 820.
12. Culman, J. & T. Unger. 1995. Central tachykinins: mediators of defence reaction and stress reactions. Can. J. Physiol. Pharmacol. 73 : 885 891.
13. Herpfer, I. & K. Lieb. 2005. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19 : 275 293.
14. Kramer, M.S., N. Cutler, J. Feighner, et al. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 : 1640 1645.
15. Smith, D.W., L. Hewson, P. Fuller, et al. 1999. The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala. Brain Res. 848 : 90 95.
16. Steinberg, R., R. Alonso, L. Rouquier, et al. 2002. SSR240600 (R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl acetyl]-2-(3,4-dichloro phenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 303 : 1180 1188.
17. Landgraf, R. & I.D. Neumann. 2004. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 25 : 150 176.
18. Wotjak, C.T., R. Landgraf & M. Engelmann. 2008. Listening to neuropeptides by microdialysis: Echoes and new sounds? Pharmacol. Biochem. Behav. 90 : 125 134.
19. Brodin, E., N. Lindefors & U. Ungerstedt. 1983. Potassium evoked in vivo release of substance P in rat caudate nucleus measured using a new technique of brain dialysis and an improved substance P-radioimmunoassay. Acta Physiol. Scand. Suppl. 515 : 17 20.
20. Ebner, K. & N. Singewald. 2006. The role of substance P in stress and anxiety responses. Amino Acids 31 : 251 272.
21. Ebner, K., N.M. Rupniak, A. Saria & N. Singewald. 2004. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA 101 : 4280 4285.
22. Ebner, K., G.M. Singewald, N. Whittle, et al. 2008. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 33 : 1929 1941.
23. Roberts, G.W., P.L. Woodhams, J.M. Polak & T.J. Crow. 1982. Distribution of neuropeptides in the limbic system of the rat: the amygdaloid complex. Neuroscience 7 : 99 131.
24. Takayama, H., Z. Ota & N. Ogawa. 1986. Effect of immobilization stress on neuropeptides and their receptors in rat central nervous system. Regul. Pept. 15 : 239 248.
25. Mantyh, P.W., C.J. Allen, J.R. Ghilardi, et al. 1995. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. USA 92 : 2622 2626.
26. Ebner, K. & N. Singewald. 2007. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn-Schmiedebergs. Arch. Pharmacol. 376 : 73 82.
27. Berton, O., H.E. Covington 3rd., K. Ebner, et al. 2007. Induction of deltaFosB in the periaqueductal gray by stress promotes active coping responses. Neuron 55 : 289 300.
28. Nestler, E.J., M. Barrot, R.J. Dileone, et al. 2002. Neurobiology of depression. Neuron 34 : 13 25.
29. Slattery, D.A., A.L. Hudson & D.J. Nutt. 2004. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 18 : 1 21.
30. Singewald, N., G.G. Chicchi, C.C. Thurner, et al. 2008. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J. Neurochem. 106 : 2476 2488.
31. Landgraf, R. & A. Wigger. 2002. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behav. Genet. 32 : 301 314.
32. Sartori, S.B., K. Ebner, P. Muigg, et al. 2005. Differences in substance P neurotransmission between rats with high vs. low trait anxiety/depression [abstract]. J. Neurochem. 94 : 229.
33. Geracioti, T.D. Jr., L.L. Carpenter, M.J. Owens, et al. 2006. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry 163 : 637 643.
34. Michelgard, A., L. Appel, A. Pissiota, et al. 2007. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol. Psychiatry 61 : 1002 1006.
35. Whitnall, M.H. 1993. Regulation of the hypothalamic corticotropin- releasing hormone neurosecretory system. Prog. Neurobiol. 40 : 573 629.
36. Antoni, F.A. 1986. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr. Rev. 7 : 351 378.
37. Hahn, M.K. & M.J. Bannon. 1999. Stress-induced c-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation. Neuroscience 94 : 1183 1188.
38. Muigg, P., S.B. Sartori, T. Sparber, et al. 2005. Reduced depression-like behaviour in HAB rats after NK1-receptor antagonist treatment is associated with an altered neuronal activation pattern in specific brain areas [abstract]. Abstract at the Meeting of the Austrian Neuroscience Association.
39. Hahn, M.K. & M.J. Bannon. 1998. Tachykinin NK1 receptor antagonists enhance stress-induced c-fos in rat locus coeruleus. Eur. J. Pharmacol. 348 : 155 160.
40. Santarelli, L., G. Gobbi, P. Blier & R. Hen. 2002. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J. Clin. Psychiatry 63 (Suppl. 11 11 17.
41. McCutcheon, J.E., A.S. Fisher, E. Guzdar, et al. 2008. Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout. Eur. J. Neurosci. 27 : 683 690.
42. Duncan, G.E., D.J. Knapp & G.R. Breese. 1996. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res. 713 : 79 91.
43. Silveira, M.C., G. Sandner & F.G. Graeff. 1993. Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze. Behav. Brain Res. 56 : 115 118.
44. File, S.E., H. Zangrossi, Jr., F.L. Sanders & P.S. Mabbutt. 1994. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology 113 : 543 546.
45. Rodgers, R.J., J. Haller, A. Holmes, et al. 1999. Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiol. Behav. 68 : 47 53.
46. Paxinos, G. & C. Watson. 1998. The Rat Brain in Stereotaxic Coordinates. Academic Press. New York.
47. Singewald, N., P. Salchner & T. Sharp. 2003. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry 53 : 275 283.
48. Pellow, S., P. Chopin, S.E. File & M. Briley. 1985. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 : 149 167.
49. Adell, A., E. Castro, P. Celada, et al. 2005. Strategies for producing faster acting antidepressants. Drug Discov. Today 10 : 578 585.
50. Singewald, N. 2007. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci. Biobehav. Rev. 31 : 18 40.
51. Kovacs, K.J. 1998. c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem. Int. 33 : 287 297.
52. Hoffman, G.E. & D. Lyo. 2002. Anatomical markers of activity in neuroendocrine systems: Are we all 'fos-ed out'? J. Neuroendocrinol. 14 : 259 268.
53. Swanson, L.W., P.E. Sawchenko & R.W. Lind. 1986. Regulation of multiple peptides in CRF parvocellular neurosecretory neurons: implications for the stress response. Prog. Brain Res. 68 : 169 190.
54. Mantyh, P.W., T. Gates, C.R. Mantyh & J.E. Maggio. 1989. Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J. Neurosci. 9 : 258 279.
55. Sawchenko, P.E., E.R. Brown, R.K. Chan, et al. 1996. The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Prog. Brain Res. 107 : 201 222.
56. Li, H.Y. & P.E. Sawchenko. 1998. Hypothalamic effector neurons and extended circuitries activated in "neurogenic" stress: a comparison of footshock effects exerted acutely, chronically, and in animals with controlled glucocorticoid levels. J. Comp. Neurol. 393 : 244 266.
57. Mello, D.M., D.R. Marcinichen, D. Madruga, et al. 2007. Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P. Behav. Brain Res. 181 : 232 238.
58. Santarelli, L., G. Gobbi, P.C. Debs, et al. 2001. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA 98 : 1912 1917.
59. Rupniak, N.M., E.J. Carlson, J.K. Webb, et al. 2001. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol. 12 : 497 508.
60. Kalman, B.A., P.J. Kim, M.A. Cole, et al. 1997. Diazepam attenuation of restraint stress-induced corticosterone levels is enhanced by prior exposure to repeated restraint. Psychoneuroendocrinology 22 : 349 360.
61. Imaki, T., X.Q. Wang, T. Shibasaki, et al. 1995. Chlordiazepoxide attenuates stress-induced activation of neurons, corticotropin-releasing factor (CRF) gene transcription and CRF biosynthesis in the paraventricular nucleus (PVN). Brain Res. Mol. Brain Res. 32 : 261 270.
62. Sheehan, T.P., R.A. Chambers & D.S. Russell. 2004. Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res. Brain Res. Rev. 46 : 71 117.
63. Risold, P.Y. 2004. The septal region. In The Rat Nervous System. G. Paxinos, Ed. : 605 632. Academic Press. New York.
64. Risold, P.Y. & L.W. Swanson. 1997. Chemoarchitecture of the rat lateral septal nucleus. Brain Res. Brain Res. Rev. 24 : 91 113.
65. Risold, P.Y. & L.W. Swanson. 1997. Connections of the rat lateral septal complex. Brain Res. Brain Res. Rev. 24 : 115 195.
66. Mongeau, R., G.A. Miller, E. Chiang & D.J. Anderson. 2003. Neural correlates of competing fear behaviors evoked by an innately aversive stimulus. J. Neurosci. 23 : 3855 3868.
67. Staiger, J.F. & F.G. Wouterlood. 1990. Efferent projections from the lateral septal nucleus to the anterior hypothalamus in the rat: a study combining Phaseolus vulgaris-leucoagglutinin tracing with vasopressin immunocytochemistry. Cell Tissue Res. 261 : 17 23.
68. Herman, J.P., H. Figueiredo, N.K. Mueller, et al. 2003. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24 : 151 180.
69. Walker, D.L., D.J. Toufexis & M. Davis. 2003. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur. J. Pharmacol. 463 : 199 216.
70. Davis, M., D.L. Walker & Y. Lee. 1997. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann. N.Y. Acad. Sci. 821 : 305 331.
71. Boyce, S., D. Smith, E. Carlson, et al. 2001. Intra-amygdala injection of the substance P antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs K(1) receptor. Neuropharmacology 41 : 130 137.
72. Sergeyev, V., S. Fetissov, A.A. Mathe, et al. 2005. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology 178 : 115 124.
73. Zhao, Z., Y. Yang, D.L. Walker & M. Davis. 2008. Effects of Substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear/potentiated startle. Neuropsychopharmacology : In press.
74. Knapska, E., K. Radwanska, T. Werka & L. Kaczmarek. 2007. Functional internal complexity of amygdala: focus on gene activity mapping after behavioral training and drugs of abuse. Physiol. Rev. 87 : 1113 1173.
75. Baulmann, J., H. Spitznagel, T. Herdegen, et al. 2000. Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain. Neuroscience 95 : 813 820.
76. Furmark, T., L. Appel, A. Michelgard, et al. 2005. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58 : 132 142.